JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Real world data of carfilzomib once weekly dosing in patients with relapsed and refractory multiple myeloma: a retrospective single center experience
Abstract
Aims: Relapsed or refractory multiple myeloma (RRMM) remains a therapeutic challenge due to treatment resistance, comorbidities, and limited options after multiple therapy lines. Carfilzomib, a second-generation proteasome inhibitor, has demonstrated efficacy when administered once weekly at 70 mg/m² in combination with dexamethasone (wKd70), offering a convenient and effective alternative to twice-weekly schedules.We conducted a retrospective analysis of 32 RRMM patients treated with wKd70 between 2018 and 2023 at a single referral center.
Methods: Thirty-two RRMM patients were analyzed retrospectively. Patients with RRMM who received at least one course of carfilzomib at a dose of 70 mg/m² (administered on days 1, 8, and 15 of 28-day cycles) in combination with dexamethasone 40 mg/week were included in the study.
Results: The median age was 57.5 years (range: 43–75), and patients had received a median of three prior therapy lines. The overall response rate (ORR) was 62.1% . Median progression-free survival (PFS) was 16 months, and median overall survival (OS) was 51 months . Prior autologous stem cell transplantation was associated with significantly improved PFS and OS. Adverse events were common but mostly mild (grades 1–2) forms.
Conclusion: Our findings support wKd70 as an effective and well-tolerated treatment option for RRMM, even in heavily pretreated patients. The favorable survival outcomes compared to historical trials suggest a role for earlier use of this regimen.

Keywords : RRMM, carfilzomib , dexamethasone, progression free survival, autologous stem cell transplantation

Download Article


1. Callander NS, Mangan PA, Kumar SK. Updates to management of multiple myeloma. J Nat Comprehensive Cancer Network. 2025; 23(Supplement):e255008. doi:10.6004/jnccn.2025.5008
2. Groen K, van de Donk N, Stege C, Zweegman S, Nijhof IS. Carfilzomib for relapsed and refractory multiple myeloma.Cancer Manag Res. 2019; 11:2663-2675. doi:10.2147/CMAR.S150653
3. Berenson JR, Cartmell A, Bessudo A, et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016;127(26):3360-3368. doi:10.1182/blood-2015-11-683854
4. Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953-964. doi:10.1016/S1470-2045(18)30354-1
5. Trautmann-Grill K, Kossack N, El Hadad L, et al. (2024). Real-world use of carfilzomib for the treatment of relapsed/refractory multiple myeloma in Germany: once-weekly and twice-weekly administration schedules. Blood. 2024;144:7826. doi:10.1182/blood-2024-198394
6. Dong S, Banerjee R, Khan AM, et al. Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis. Blood Cancer J. 2025;15(1):48. doi:10.1038/s41408-025-01256-2
7. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.Lancet Oncol. 2016;17(8):e328-e346. doi:10.1016/S1470-2045(16)30206-6
8. Dimopoulos MA, Niesvizky R, Weisel K, et al. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. Blood Cancer J. 2020;10(3):35. doi:10.1038/s41408-020-0300-y
9. Park SS, Goo SY, Jeon YW, Yhang SA, Shin SH, Min CK. Real-world treatment outcomes of carfilzomib plus dexamethasone in patients with relapsed and/or refractory multiple myeloma, focusing on the impact of trial-fitness: CAtholic REsearch network for multiple myeloma study (CAREMM-2203). J Cancer Res Clin Oncol. 2023;149(18):16279-16291. doi:10.1007/s00432-023-05385-8
10. Abe Y, Kubonishi S, Ri M, et al. An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study). Future Oncol. 2024;20(17):1191-1205. doi:10.2217/fon-2023-0834
11. Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017;177(3):404-413. doi:10.1111/bjh.14549
12. Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327-1337. doi:10.1016/S1470-2045(17)30578-8
13. Quach H, Kim K, Wong RSM, et al. Real-world use of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd) in relapsed/refractory multiple myeloma in the Asia Pacific Region: a prospective multicenter observational study.Clin Lymphoma Myeloma Leuk. 2025;25(11):e886-e898. doi:10.1016/j.clml.2025.05.001
14. Knauf W, Uhlig J, von der Heyde E, et al. Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study.Leuk Lymphoma. 2025;66(4):691-701. doi:10.1080/10428194.2024.2436034
Article available in :
Volume 4, Issue 3, 2026
Page : 105-109
https://doi.org/10.51271/JCHOR-0091
Article Information
Received : 04 Haz 2026
Accepted : 10 Tem 2026
Published : 08 Ağu 2026
Corresponding Author :

Meral Uluköylü Mengüç: Department of Hematology, Faculty of Medicine, Yeditepe University, İstanbul, Turkiye

[email protected]
Citation : Uluköylü Mengüç M, Şişman İT, Arıkan F, et al. Real world data of carfilzomib once weekly dosing in patients with relapsed and refractory multiple myeloma: single center experience. J Curr Hematol Oncol Res. 2026;4(3):105-109. doi:10.51271/JCHOR-0091

Read: 383
Download : 242
Cited: 0
_Footer